Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Retained Earnings for 9 consecutive years, with -$1.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 28061850.0% to -$1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.7 billion, a 28061850.0% decrease, with the full-year FY2025 number at -$1.7 billion, down 28061850.0% from a year prior.
  • Retained Earnings was -$1.7 billion for Q4 2025 at Akebia Therapeutics, down from $6000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $9000.0 in Q1 2021 to a low of -$1.7 billion in Q4 2025.
  • A 5-year average of -$1.0 billion and a median of -$1.5 billion in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2021, then plummeted 28061850.0% in 2025.
  • Akebia Therapeutics' Retained Earnings stood at -$1.5 billion in 2021, then fell by 6.44% to -$1.6 billion in 2022, then surged by 100.0% to $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then tumbled by 28061850.0% to -$1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Retained Earnings are -$1.7 billion (Q4 2025), $6000.0 (Q3 2025), and -$1.7 billion (Q2 2025).